Interaction of terbinafine (anti-fungal agent) with perhexiline: a case report

Abdul Rauf Sheikh1, Ian Westley2, Benedetta Sallustio3

  • 1The Discipline of Medicine, The Queen Elizabeth Hospital, The University of Adelaide, Adelaide, South Australia; Cardiology Unit, The Queen Elizabeth Hospital, Central Adelaide Local Health Network.

Heart, Lung & Circulation
|December 31, 2013
PubMed

Insights

The anti-anginal drug perhexiline can reach toxic levels when taken with terbinafine, a CYP2D6 inhibitor. This interaction highlights the importance of monitoring perhexiline levels during co-administration with CYP2D6 inhibiting medications.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Clinical Toxicology

Background:

  • Perhexiline is an anti-anginal medication used for chronic refractory angina.
  • Its use is limited by complex pharmacokinetics, particularly its metabolism.
  • Perhexiline is primarily metabolized by cytochrome P450 2D6 (CYP2D6).

Observation:

  • Cytochrome P450 2D6 (CYP2D6) inhibitors can impede perhexiline metabolism.
  • This inhibition can lead to increased plasma perhexiline concentrations and potential toxicity.
  • A case study revealed elevated perhexiline levels after initiating terbinafine hydrochloride.

Findings:

  • Terbinafine hydrochloride is identified as a moderate inhibitor of CYP2D6.
  • The introduction of terbinafine led to a significant rise in a patient's perhexiline plasma concentration.
  • Perhexiline levels reached a toxic threshold due to this drug interaction.

Implications:

  • Clinicians should exercise caution when prescribing CYP2D6 inhibitors with perhexiline.
  • Therapeutic drug monitoring of perhexiline is crucial when co-administering with CYP2D6 inhibitors.
  • Understanding drug-drug interactions involving CYP2D6 is vital for patient safety and effective angina treatment.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
119
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.2K
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
695
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
103
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
813